Vindesine

DB00309ApprovedInvestigationalWithdrawnSmall molecule

Vindesine is a vinca alkaloid derived from vinblastine used for various types of malignancies, but mainly acute lymphocytic leukemia (ALL). Vinblastine derivative with antineoplastic activity against cancer.

Mechanism: Vindesine acts by causing the arrest of cells in metaphase mitosis through its inhibition tubulin mitotic funcitoning. The drug is cell-cycle specific for the S phase.
Curator reviewed
Primary indication: For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosisCurator reviewed · 3 structured indications
Formula / weight: C₄₃H₅₅N₅O₇ · 753.941 g/mol (avg)
First approval: Canada, 1982
Also known as: Desacetylvinblastine amide
Code names: Lilly 112531

Resolves to

Compound

UNIIRSA8KO39WHCAS53643-48-4ChEMBLCHEMBL238071ChEBI36373PubChem40839KEGGD01769

Clinical / RWD

RxNorm11204ATCL01CA03PharmGKBPA10232

Structure

InChIKeyHHJUWIANJFBDHT-ZVTSDNJWSA-NSMILES

[H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(N)=O)[C@]1(C[C@@]2([H])CN(C[C@](O)(CC)C2)CCC2=C1NC1=C2C=CC=C1)C(=O)OC

Targets

Q9H4B7TUBB1

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

934Drug interactionsStructured to mechanism, not free text

61Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

2ContraindicationsEach with its own population and attribute set

4Marketed productsAcross 3 countries and 3 labellers

1ATC codeIncluding every combination product, plus 22 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vindesine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account